COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19
Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
In a randomized, double-blind, placebo-controlled, multi-center, Phase 2-like,
investigator-directed trial, hospitalized adult patients with laboratory confirmed SARS-CoV-2
infection meeting inclusion and exclusion criteria, will be provided information on the
trial, offered enrollment, and if informed consent provided, enrolled randomly in a 2:1 ratio
to one of two groups: Group 1 standard care and losartan or Group 2 standard care and
placebo. Patients will be followed for up to 60 days, with data collected to quantify the
NCOSS over time (the primary objective), and for the trial's secondary objectives (see
outcome measurements below).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Bassett Healthcare
Collaborators:
Goshen Health System Reid Health
Treatments:
Coal Tar Hydroxychloroquine Lopinavir Losartan Ritonavir